Wealthcare Advisory Partners LLC Sells 9,707 Shares of Bristol Myers Squibb Company $BMY

Wealthcare Advisory Partners LLC reduced its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 21.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 35,781 shares of the biopharmaceutical company’s stock after selling 9,707 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Bristol Myers Squibb were worth $1,930,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Wincap Financial LLC increased its position in shares of Bristol Myers Squibb by 2.2% during the fourth quarter. Wincap Financial LLC now owns 20,451 shares of the biopharmaceutical company’s stock worth $1,103,000 after acquiring an additional 437 shares in the last quarter. Pallas Capital Advisors LLC lifted its position in Bristol Myers Squibb by 196.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 96,157 shares of the biopharmaceutical company’s stock valued at $5,187,000 after acquiring an additional 63,750 shares in the last quarter. Hourglass Capital LLC bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $234,000. KMG Fiduciary Partners LLC boosted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. KMG Fiduciary Partners LLC now owns 43,150 shares of the biopharmaceutical company’s stock worth $2,328,000 after purchasing an additional 592 shares during the period. Finally, Net Worth Advisory Group bought a new position in Bristol Myers Squibb during the 4th quarter worth about $909,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Barclays began coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective for the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Leerink Partners boosted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase 3 SCOUT‑HCM data for Camzyos (mavacamten) in adolescents showed efficacy and safety, increasing the drug’s addressable market and raising the chance of label expansion and incremental sales for BMY’s cardiovascular franchise. Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT‑HCM Trial
• Positive Sentiment: The FDA granted approval for BMY’s combination regimen in Hodgkin’s lymphoma (announced March 20), adding a near‑term revenue stream and supporting sentiment around the oncology portfolio. Bristol‑Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Neutral Sentiment: Phase 4 data for Cobenfy (xanomeline+tropium) presented safety/tolerability data in switching patients, which could reshape long‑term revenue assumptions if follow‑on studies or real‑world switching data are favorable — outcome still uncertain for valuation impact. Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Analyses highlight growth opportunities in the pancreatic adenocarcinoma market (projected high CAGR) where BMY is named among major players — long‑term tailwind but competitive landscape and timing of launches matter. Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR
• Neutral Sentiment: Several financial writeups point to BMY as an income/dividend name and note an upcoming ex‑dividend date; that can support demand from yield‑focused investors but doesn’t change fundamentals. Bristol‑Myers Squibb Looks Like A Good Stock, And It’s Going Ex‑Dividend Soon
• Negative Sentiment: Analyst coverage is mixed — roughly 60% of covering analysts have non‑bullish ratings even though the consensus price target implies limited upside, which could cap upside until guidance or earnings beat expectations and analysts raise targets. Bristol‑Myers Squibb Faces Mixed Analyst Sentiment

Bristol Myers Squibb Trading Up 2.1%

Bristol Myers Squibb stock opened at $59.76 on Tuesday. The company has a market cap of $122.01 billion, a price-to-earnings ratio of 17.32, a P/E/G ratio of 0.17 and a beta of 0.26. The firm has a 50-day moving average of $58.91 and a 200-day moving average of $52.35. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the firm posted $1.67 EPS. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.